Clinical trial
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
NCT01328379
Study timeline
Study start (unknown)2011-03-01Date precision: month
Registry last updated2013-09-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
Sponsors & collaborators
Acorda Therapeuticslead sponsor
Mapped research locations
HoustonTexas, United States2PhiladelphiaPennsylvania, United States2ColumbusOhio, United States2PortlandOregon, United States2IndianapolisIndiana, United States2CharlotteNorth Carolina, United States2RichmondVirginia, United States2Des MoinesIowa, United States2New YorkNew York, United States1ChicagoIllinois, United States1DallasTexas, United States1BaltimoreMaryland, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01328379 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.